• LAST PRICE
    0.0550
  • TODAY'S CHANGE (%)
    Trending Down-0.0050 (-8.3333%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0600 / 0.0600
  • Day Range
    Low 0.0450
    High 0.0600
  • 52 Week Range
    Low 0.0050
    High 0.1350
  • Volume
    200,000
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.06
TimeVolumeRKV
09:32 ET50000.06
11:59 ET500000.05
01:47 ET310000.045
01:56 ET50000.05
02:54 ET50000.05
03:10 ET40000.05
03:55 ET150000.055
03:57 ET850000.055
04:00 ET620000.055
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
CanadaRKV
Rakovina Therapeutics Inc
5.0M
-1.3x
---
CanadaQPT
Quest Pharmatech Inc
5.1M
0.4x
---
CanadaGTTX
GeneTether Therapeutics Inc
3.9M
-4.7x
---
CanadaASEP
Asep Medical Holdings Inc
4.5M
-0.8x
---
CanadaAWKN
Awakn Life Sciences Corp
4.6M
-1.2x
---
CanadaRVV
Revive Therapeutics Ltd
4.2M
-0.7x
---
As of 2024-11-22

Company Information

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. The Company is focused on the development of new cancer treatments based on novel deoxyribonucleic acid (DNA)-damage response technologies. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase (HDAC) in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.

Contact Information

Headquarters
105 - 1008 Beach AvenueVancouver, BC, Canada V6E 1T7
Phone
604-619-0225
Fax
604-980-6264

Executives

Executive Chairman of the Board
Jeffrey Bacha
President, Chief Scientific Officer
Mads Daugaard
Independent Non-Executive Vice Chairman of the Board
Alfredo De Lucrezia
Chief Financial Officer
David Hyman
Chief Operating Officer
John Langlands

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$5.0M
Revenue (TTM)
$0.00
Shares Outstanding
90.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.10
EPS
$-0.04
Book Value
$0.05
P/E Ratio
-1.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.